Upcoming Lupus Nephritis Pipeline
1. Gazyva (obinutuzumab) – due for FDA/EMA decision
2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN
3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/3qg1FWzZRI
Links:
Lupus Nephritis Treatment Advances: New Therapies on the Horizon Promise Better…
https://buff.ly/eaO00Ug
Jun-25-2025
